Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
We’re not a vaccine company, what is the relevance? Let me guess, “it’ll spike testing”? No, it won’t. We’ve all seen the. Numbers, covid income is finished.
Grim forecast of upcoming winter in an article in independent today .
WINTERPLEX
“Steve Russell, the NHS director for vaccinations and screening, said people should book in as early as possible once invited. “This winter will be the first time we see the real effects of both Covid and flu in full circulation as we go about life as normal — and so it is vital that those most susceptible to serious illness from these viruses come forward for the latest jab in order to protect themselves,” he said.”
I do not hold avct and don’t intend to therefore not wasting my time researching them.
Correct, fundamentally different.
Avct sp not based on diagnostics, but on therapeutics. Worth a huge amount of research.if you can be bothered.
Marcap of 11.5x cash whereas ours is about 0.8. Other than dhsc, it really makes no sense. Their business must be fundamentally different
Nobody has ripped off the public purse , Novacyt supplied tests that have been used globally , for reasons unknown to us the DHSC and Novacyt are in dispute. They didn't fail to supply and have kept the money , they didn't send out smarties instead of covid tests. Your emotive language is deliberate and designed to instil fear.
The company has adequate funds to make an acquisition and a superb R and D team. Now whether Allmond can steer the ship is another matter entirely.
Non covid sales some 40% down on 2019. After two years of growth, **** tonne of cash, new networks. Fairly sure the dispute hasn’t helped in the pursuit of new sales. Not saying it has been but potentially ripping off the public purse during a health emergency isn’t a great look.
No they havent P100 , but nor are we ? If you don't understand basic accounting then you shouldn't invest. You understand fully how the claim is calculated yet still post B/S
"their reputation totally destroyed by a dhsc dispute?"
Proof of statement above P100, please
Have they had their reputation totally destroyed by a dhsc dispute? Are they being sued for 135% of their cash?
Sir D chuckle chucke.
I said “in the eyes of the market”. Literally saying in someone’s else’s eyes, not mine. Therefore I can’t enlighten you.
Please enlighten us P100.
AVCT Financial and Corporate highlights
· Cash and short-term deposit balances at 31 December 2021 of £26.2 million (31 December 2020: £47.9 million).
· Revenues of £2.9 million for year ended 31 December 2021 (year ended 31 December 2020: £2.1 million).
· Operating loss of £29.1 million for year ended 31 December 2021 (year ended 31 December 2020: £18.8 million).
· Increased R&D and manufacturing investment within the Diagnostics Division and clinical development costs in the Therapeutics Division, leading to reported loss from continuing operations of £26.4 million (year ended 31 December 2020: £16.4 million).
They clearly have a viable business going forward, in the eyes of the market.
Well it's going to devastate you when you realize their market cap is over 4 times ours, which after all is what matters as a metric.
.................never thought I'd see the day when the share price of AVCT would be more than here, not good!!!!!!!!